Eli Lil­ly is go­ing big on in vi­vo CAR-T ther­a­py. The com­pa­ny said Mon­day that it would buy Kelo­nia Ther­a­peu­tics, which has a Phase 1 pro­gram for mul­ti­ple myelo­ma and a cou­ple of pre­clin­i­cal can­di­dates, in a deal worth up to $7 bil­lion that in­cludes $3.25 bil­lion up­front...